GOLPH2 expression may serve as diagnostic marker in seminomas

BMC Urology

Volumn 10, Issue , 2010, Pages

  Fritzsche, Florian R ^a   Kristiansen, Glen ^a   Riener, Marc Oliver ^b   Dietel, Manfred ^c   Oelrich, Beibei ^d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GOLGI PHOSPHOPROTEIN 2; PHOSPHOPROTEIN; UNCLASSIFIED DRUG; GOLM1 PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER OF UNKNOWN PRIMARY SITE; CONTROLLED STUDY; DIAGNOSTIC TEST; GENE EXPRESSION; GENE OVEREXPRESSION; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRATUBULAR GERM CELL NEOPLASIA OF UNCLASSIFIED TYPE; LEYDIG CELL; LEYDIG CELL TUMOR; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; SEMINOMA; STAINING; TESTIS; TESTIS CANCER; METABOLISM; MIDDLE AGED; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TESTIS TUMOR;

ADULT; AGED; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SEMINOMA; SENSITIVITY AND SPECIFICITY; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77949901820     PISSN: 14712490     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-10-4     Document Type: Article

References (21)

1. Doubling of testicular cancer incidence rate over the last 20 years in southern France. M Walschaerts E Huyghe A Muller JM Bachaud L Bujan P Thonneau, Cancer Causes Control 2008 19 2 155 161
2. Testicular cancer: trends in mortality are well explained by changes in treatment and survival in the southern Netherlands since 1970. RH Verhoeven JW Coebergh LA Kiemeney EL Koldewijn S Houterman, Eur J Cancer 2007 43 17 2553 2558
3. Recent developments in testicular germ cell tumor research. GJ van de Geijn R Hersmus LH Looijenga, Birth Defects Res C Embryo Today 2009 87 1 96 113
4. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. G Kristiansen FR Fritzsche K Wassermann C Jager A Tolle M Lein C Stephan K Jung C Pilarsky M Dietel, et al. Br J Cancer 2008 99 6 939 948
5. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. B Laxman DS Morris J Yu J Siddiqui J Cao R Mehra RJ Lonigro A Tsodikov JT Wei SA Tomlins, et al. Cancer Res 2008 68 3 645 649
6. Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. C Bachert C Fimmel AD Linstedt, Traffic 2007 8 10 1415 1423
7. Disease- and cell-specific expression of GP73 in human liver disease. R Iftikhar RD Kladney N Havlioglu A Schmitt-Graff I Gusmirovic H Solomon BA Luxon BR Bacon CJ Fimmel, Am J Gastroenterol 2004 99 6 1087 1095
8. GP73, a novel Golgi-localized protein upregulated by viral infection. RD Kladney GA Bulla L Guo AL Mason AE Tollefson DJ Simon Z Koutoubi CJ Fimmel, Gene 2000 249 1-2 53 65
9. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. RD Kladney X Cui GA Bulla EM Brunt CJ Fimmel, Hepatology 2002 35 6 1431 1440
10. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. JA Marrero PR Romano O Nikolaeva L Steel A Mehta CJ Fimmel MA Comunale A D'Amelio AS Lok TM Block, J Hepatol 2005 43 6 1007 1012
11. Decreased Survival and Hepato-Renal Pathology in Mice with C-Terminally Truncated GP73 (GOLPH2). LM Wright S Yong MM Picken D Rockey CJ Fimmel, Int J Clin Exp Pathol 2009 2 1 34 47
12. ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. FR Fritzsche K Wassermann M Jung A Tolle I Kristiansen M Lein M Johannsen M Dietel K Jung G Kristiansen, BMC Cancer 2008 8 179
13. Delineation of prognostic biomarkers in prostate cancer. SM Dhanasekaran TR Barrette D Ghosh R Shah S Varambally K Kurachi KJ Pienta MA Rubin AM Chinnaiyan, Nature 2001 412 6849 822 826
14. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. MO Riener F Stenner H Liewen C Soll S Breitenstein BC Pestalozzi P Samaras N Probst-Hensch C Hellerbrand B Mullhaupt, et al. Hepatology 2009 49 5 1602 1609
15. GOLPH2 and MYO6: Putative prostate cancer markers localized to the Golgi apparatus. S Wei TA Dunn WB Isaacs AM De Marzo J Luo, Prostate 2008 68 13 1387 1395
16. An in-depth look at Leydig cell tumor of the testis. OM Al-Agha CA Axiotis, Arch Pathol Lab Med 2007 131 2 311 317
17. Morphological approach to tumours of the testis and paratestis. RE Emerson TM Ulbright, J Clin Pathol 2007 60 8 866 880
18. GOLPH2 expression in renal cell cancer. FR Fritzsche MO Riener M Dietel H Moch K Jung G Kristiansen, BMC Urol 2008 8 15
19. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. TM Block MA Comunale M Lowman LF Steel PR Romano C Fimmel BC Tennant WT London AA Evans BS Blumberg, et al. Proc Natl Acad Sci USA 2005 102 3 779 784
20. Upregulation of the Golgi protein GP73 by adenovirus infection requires the E1A CtBP interaction domain. RD Kladney AE Tollefson WS Wold CJ Fimmel, Virology 2002 301 2 236 246
21. Risk factors for benign prostatic hyperplasia. SJ Jacobsen, Curr Urol Rep 2007 8 4 281 288